MYC and gastric cancer: A pan-HER inhibitor, PF0029984, was tested in seven gastric cancer cell lines, each having one of the following abnormalities: KRAS mutation; amplification of FGFR2, MYC (V-Myc avian myelocytomatosis viral oncogene homolog) or MET (MET proto-oncogene receptor tyrosine kinase).